Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07691489 · ClinicalTrials.gov registry record · Phase 2
A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Not yet
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT07691489: Clinical Trial Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT07691489 is a Phase 2 study that has not yet begun recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07691489, a Phase 2 study, has not yet begun recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this study is find out whether the combination of trastuzumab deruxtecan (T-DXd) and cetuximab is an effective treatment for participants with metastatic and/or unresectable colorectal cancer that expresses low levels of HER2 and that has gotten worse after receiving standard treatment.
Interventions
- DRUG Fam-Trastuzumab Deruxtecan-Nxki
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2026-08 |
| Est. Completion | 2029-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07691489
The ClinicalTrials.gov registry entry for NCT07691489 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fam-Trastuzumab Deruxtecan-Nxki is the first listed.
NCT07691489 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07691489 about?
NCT07691489 is a clinical study titled "A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer". The purpose of this study is find out whether the combination of trastuzumab deruxtecan (T-DXd) and cetuximab is an effective treatment for participants with metastatic and/or unresectable colorectal cancer that expresses low levels of HER2 and that has gotten worse after receiving standard treatmen...
What is the current status of trial NCT07691489?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2026-08. Estimated completion is 2029-06.
What interventions are being tested in trial NCT07691489?
The interventions under investigation include: Fam-Trastuzumab Deruxtecan-Nxki (DRUG).
Who is sponsoring clinical trial NCT07691489?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.